Pathfinder Cell Therapy (Pathfinder Cell Therapy) ROCE % : 0.00% (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pathfinder Cell Therapy's annualized ROCE % for the quarter that ended in Sep. 2015 was 0.00%.

Pathfinder Cell Therapy ROCE % Historical Data

The historical data trend for Pathfinder Cell Therapy's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy ROCE % Chart

Pathfinder Cell Therapy Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

ROCE %

Get a 7-Day Free Trial

Pathfinder Cell Therapy Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Pathfinder Cell Therapy ROCE % Calculation

Pathfinder Cell Therapy's annualized ROCE % for the fiscal year that ended in Dec. 2014 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2014 )		(A: Dec. 2013 )		(A: Dec. 2014 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2014 )		(A: Dec. 2013 )		(A: Dec. 2014 )
	=	-1.119	/	( ( (0.155 - 4.706)	+	(0.106 - 6.049) )	/ 2 )
	=	-1.119	/	( (-4.551	+	-5.943)	/ 2 )
	=	-1.119	/	-5.247
	=	21.33 %

Pathfinder Cell Therapy's ROCE % of for the quarter that ended in Sep. 2015 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2015 )		(Q: Jun. 2015 )		(Q: Sep. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2015 )		(Q: Jun. 2015 )		(Q: Sep. 2015 )
	=	-0.836	/	( ( (0.049 - 6.49)	+	(0.039 - 6.769) )	/ 2 )
	=	-0.836	/	( ( -6.441	+	-6.73 )	/ 2 )
	=	-0.836	/	-6.5855
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

Pathfinder Cell Therapy (OTCPK:PFND) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pathfinder Cell Therapy ROCE % Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Bow Street, Cambridge, MA, USA, 02138

Website

http://www.pathfindercelltherapy.com

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.

Executives

John J Alam	director	130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines